Gilead Sciences Inc.'s acquisition of privately held Cell Design Labs Inc. seemed almost preordained following its $11.9bn buyout of CAR-T specialist Kite Pharma Inc. back in October, and market analysts expect the deep-pocketed specialty firm to continue making bolt-on deals to advance its expertise and capabilities in immuno-oncology.
Gilead announced a structured buyout valued at approximately $567m for the Emeryville, Calif.-based Cell Design on Dec. 7, bringing in...